辰光医疗
(920300)
| 流通市值：7.42亿 | | | 总市值：9.57亿 |
| 流通股本：6653.17万 | | | 总股本：8584.71万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 24,678,348.47 | 89,939,697.09 | 67,742,641.82 | 47,352,708.32 |
| 营业收入 | 24,678,348.47 | 89,939,697.09 | 67,742,641.82 | 47,352,708.32 |
| 二、营业总成本 | 32,480,379.43 | 129,182,046.1 | 96,144,924.52 | 67,813,883.45 |
| 营业成本 | 14,525,916.1 | 43,095,059.93 | 34,055,730.93 | 25,506,756.35 |
| 税金及附加 | 413,137.76 | 1,835,362.09 | 1,256,593.65 | 866,136.87 |
| 销售费用 | 6,502,130.73 | 23,771,189.08 | 17,999,124.51 | 12,268,461.84 |
| 管理费用 | 4,311,212.61 | 22,650,603.49 | 15,992,189.01 | 11,094,975.08 |
| 研发费用 | 5,662,911.46 | 32,744,102.45 | 22,986,402.65 | 15,485,867.51 |
| 财务费用 | 1,065,070.77 | 5,085,729.06 | 3,854,883.77 | 2,591,685.8 |
| 其中:利息费用 | 1,043,521.98 | 4,785,040.42 | 3,751,370.82 | 2,608,486.87 |
| 其中:利息收入 | 2,475.74 | 28,334.73 | 23,989.39 | 19,730.54 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | 253,733.24 | 239,046.87 | 126,820.84 |
| 资产处置收益 | 30,025.88 | 9,666.95 | - | - |
| 资产减值损失(新) | - | -12,003,233.09 | -1,394,339.31 | -1,394,339.31 |
| 信用减值损失(新) | -294,602.51 | -4,292,374.02 | 1,733,594.67 | 1,607,880.96 |
| 其他收益 | 716,088.99 | 3,993,289.39 | 2,369,747.76 | 1,532,002.33 |
| 四、营业利润 | -7,350,518.6 | -51,281,266.54 | -25,454,232.71 | -18,588,810.31 |
| 加:营业外收入 | 50,001.31 | 37.14 | 53,006.94 | 53,598.66 |
| 减:营业外支出 | 3,788.26 | 396,685.13 | 23,142.11 | 19,162 |
| 五、利润总额 | -7,304,305.55 | -51,677,914.53 | -25,424,367.88 | -18,554,373.65 |
| 减:所得税费用 | -28,354.88 | 8,762,123.61 | -6,093,699.53 | -3,736,702.87 |
| 六、净利润 | -7,275,950.67 | -60,440,038.14 | -19,330,668.35 | -14,817,670.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -7,275,950.67 | -60,440,038.14 | -19,330,668.35 | -14,817,670.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -7,275,950.67 | -60,440,038.14 | -19,330,668.35 | -14,817,670.78 |
| 扣除非经常损益后的净利润 | -7,938,739.57 | -63,632,259.72 | -21,489,027.34 | -16,207,813.33 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.08 | -0.7 | -0.23 | -0.17 |
| (二)稀释每股收益 | -0.08 | -0.7 | -0.23 | -0.17 |
| 九、综合收益总额 | -7,275,950.67 | -60,440,038.14 | -19,330,668.35 | -14,817,670.78 |
| 归属于母公司股东的综合收益总额 | -7,275,950.67 | -60,440,038.14 | -19,330,668.35 | - |
| 公告日期 | 2026-04-29 | 2026-04-24 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |